Company Overview and News

 
Synchrony Financial (SYF) Q1 Earnings: What's in the Cards?

20h zacks
Synchrony Financial (SYF - Free Report) will release first-quarter 2018 results on Apr 20, 2018, before the market opens. Last quarter, the company delivered a positive earnings surprise of 11.11%.

 
2 Large Banks Report Soft Consumer Numbers

2018-04-15 seekingalpha
Both J.P. Morgan (JPM) and Wells Fargo (WFC) fell 2.7% and 3.4% respectively after the street was disappointed with their reported earnings and financial metrics.

 
Netflix, Bank of America, United Continental and More Earnings On Tap This Week

2018-04-15 247wallst
The U.S. broad markets ended this past up for the first time in a while. Year to date, the Dow Jones industrial average and the S&P 500 are down 1.5% and 0.6%, respectively. Although the numbers have been worse, the past week’s gain and a positive outlook for an earnings season that could very well stabilize the markets.

1
SA Stock To Watch: Netflix To The Rescue?

2018-04-14 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

 
'Very, very good' earnings season risks being overshadowed by trade, politics in week ahead

2018-04-13 cnbc
Trade talk and politics could hang over the market in the coming week, even with a blast of earnings news providing a bright spot.

 
Amazon's Checking Account Push Shows Next Target: Swipe Fees - Bloomberg

2018-04-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Stocks slip again after US proposes more China tariffs

2018-04-06 nzherald.co.nz
NEW YORK (AP) — Another increase in trade tensions has stocks reversing course and falling again Friday morning as the U.S. considers an even larger set of tariffs on imports from China. Stocks have tumbled and then climbed this week as investors tried to get a sense of whether a trade dispute between the two nations will escalate, an outcome that could have major consequences for the global economy.

1
U.S. Concrete Deserves A Higher Multiple - Cramer's Lightning Round (4/5/18)

2018-04-06 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, April 5.

 
SYF / Synchrony Financial DEF 14A

2018-04-04 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
SYF / Synchrony Financial DEFA 14A

2018-04-04 sec.gov
DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION <

1
Are Short Sellers Betting General Electric Will Kill Its Dividend?

2018-03-27 247wallst
Short interest in General Electric Co. (NYSE: GE) rose by nearly 14% in the reporting period that ended March 15. Short sellers added almost 19 million shares to their positions, and a total of 155.34 million shares (1.8% of the total float) were short.

1
Stock Spin-Offs And Superinvestors

2018-03-26 seekingalpha
Many Superinvestors (including Warren Buffett, Joel Greenblatt, and Peter Lynch) have invested in stock spin-offs to generate world-class returns.

 
A swan-song for Toys R Us, the going-out-of-business sale

2018-03-23 nzherald.co.nz
NEW YORK (AP) — Toys R Us opened its doors Friday with a going-out-of-business sale, offering clearance discounts at all 735 U.S. stores, including Babies R Us.

 
The Fingerprints Of Buffett's Next Deal

2018-03-20 seekingalpha
I looked at deals where Berkshire went in alone, or went in partners with 3G capital.

 
What Buffett And Munger Have To Say About Investing In Spinoffs

2018-03-16 valuewalk
Superinvestors and Stock Spinoffs: What Buffett, Munger, Klarman, Greenblatt, Lynch, and Pabrai Have to Say about Investing in Spinoffs

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 87165B103